Recently, a Phase Ib study investigating the use of magrolimab and azacitidine in frontline mutant TP53 AML in patients unsuitable for standard intensive chemotherapy has shown promise in achieving durable responses and improving OS [59]. This evidence concerns the gene TP53 and acute myeloid leukemia.